Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr-/- mice
- PMID: 32796843
- PMCID: PMC7429830
- DOI: 10.1038/s41467-020-17915-w
Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr-/- mice
Abstract
Lipid peroxidation generates reactive dicarbonyls including isolevuglandins (IsoLGs) and malondialdehyde (MDA) that covalently modify proteins. Humans with familial hypercholesterolemia (FH) have increased lipoprotein dicarbonyl adducts and dysfunctional HDL. We investigate the impact of the dicarbonyl scavenger, 2-hydroxybenzylamine (2-HOBA) on HDL function and atherosclerosis in Ldlr-/- mice, a model of FH. Compared to hypercholesterolemic Ldlr-/- mice treated with vehicle or 4-HOBA, a nonreactive analogue, 2-HOBA decreases atherosclerosis by 60% in en face aortas, without changing plasma cholesterol. Ldlr-/- mice treated with 2-HOBA have reduced MDA-LDL and MDA-HDL levels, and their HDL display increased capacity to reduce macrophage cholesterol. Importantly, 2-HOBA reduces the MDA- and IsoLG-lysyl content in atherosclerotic aortas versus 4-HOBA. Furthermore, 2-HOBA reduces inflammation and plaque apoptotic cells and promotes efferocytosis and features of stable plaques. Dicarbonyl scavenging with 2-HOBA has multiple atheroprotective effects in a murine FH model, supporting its potential as a therapeutic approach for atherosclerotic cardiovascular disease.
Conflict of interest statement
M.F.L., S.S.D., V.A., O.B., J.A.O., and L.J.R.II are inventors on a patent application for the use of 2-HOBA and related dicarbonyl scavengers for the treatment of cardiovascular disease. M.F.L. has received reseach funding from Amgen, Regeneron, Ionis, Merck, REGENXBIO, Sanofi and Novartis and has served as a consultant for Esperion, Alexion Pharmaceuticals and REGENXBIO. All the other authors (H.T., J.H., P.G.Y., J.L.B., F.Y., V.Y., V.Z., L.D., and I.Z.I.) declare no competing interests.
Figures
References
-
- Linton, M. F. et al. The Role of Lipids and Lipoproteins in Atherosclerosis. In: Endotext. MDText.com, Inc. (eds. De Groot, L. J. et al.). (South Dartmouth (MA), 2019). https://www.ncbi.nlm.nih.gov/pubmed/26844337.
-
- Anderson TJ. Oxidative stress, endothelial function and coronary atherosclerosis. Cardiologia. 1997;42:701–714. - PubMed
-
- Aviram M. Atherosclerosis: cell biology and lipoproteins–inflammation and oxidative stress in atherogenesis: protective role for paraoxonases. Curr. Opin. Lipidol. 2011;22:243–244. - PubMed
-
- Peluso I, Morabito G, Urban L, Ioannone F, Serafini M. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr. Metab. Immune Disord. Drug Targets. 2012;12:351–360. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
